CJC-1295 Ipamorelin Peptide Canada

Dual‑Pathway GHRH & GHSR‑1a Research Peptides for Endocrine Signalling & Receptor‑Pathway Studies

CJC‑1295 (No DAC) + Ipamorelin is a research‑grade dual‑peptide formulation widely referenced in laboratory research involving endocrine signalling, receptor co‑activation, intracellular messenger integration, and peptide‑receptor kinetics.

Supplied by BlueNex Labs, this formulation combines CJC‑1295 (No DAC)—a short‑acting GHRH analogue—with Ipamorelin, a selective GHSR‑1a agonist. Together, they support controlled investigation of parallel receptor systems under Research‑Use‑Only (RUO) conditions in Canadian research environments.

This dual‑peptide system is commonly used as a model platform for studying how GHRH receptor (GHRH‑R) signalling and growth hormone secretagogue receptor (GHSR‑1a) signalling behave independently and in combination.

Unlike DAC‑modified peptides, CJC‑1295 (No DAC) lacks a drug‑affinity complex, resulting in short‑window receptor engagement. This property makes it particularly useful for high‑resolution kinetic studies and time‑course experiments focused on pulsatile receptor activation patterns.

When paired with Ipamorelin, researchers can explore dual‑pathway signalling architecture without long‑acting peptide confounders.

This formulation contains two distinct research peptides:

CJC‑1295 (No DAC)

• Synthetic GHRH analogue without DAC modification
• Used in laboratory models of GHRH‑R binding and cAMP‑linked signalling
• Short in‑vitro half‑life supports temporal resolution studies

Ipamorelin

• Selective GHSR‑1a pentapeptide agonist
• Used in studies of Ca²⁺ mobilization and receptor‑bias behaviour
• Demonstrates predictable, receptor‑specific signalling in vitro

Together, this combination enables dual‑axis endocrine signalling research under controlled laboratory conditions.

Dual‑Receptor Pathway Activation

• Used to study simultaneous GHRH‑R and GHSR‑1a engagement
• Supports analysis of receptor crosstalk and pathway amplification
• Applied in comparative single‑ vs. dual‑receptor studies

⚙️ Intracellular Messenger Integration

• Referenced in research examining cAMP signalling (GHRH‑R)
• Supports studies of Ca²⁺ mobilization (GHSR‑1a)
• Enables mapping of convergent vs. divergent transcriptional responses

🔁 Receptor Bias & Kinetic Behaviour

• Applied in assays measuring β‑arrestin recruitment and receptor internalization
• Used for receptor recycling and ligand‑dependent trafficking studies
• Supports short‑window kinetic modelling due to No‑DAC design

Type: Dual‑peptide research formulation

Form: Lyophilized powder

Fill Size:

• 5 mg CJC‑1295 (No DAC)
• 5 mg Ipamorelin

Identity Verification:

• Each peptide independently verified via Mass Spectrometry (MS)
• Purity confirmed by HPLC / UPLC

Structural & Biochemical Notes

CJC‑1295 (No DAC):

• Short‑acting GHRH analogue without albumin‑binding modification
• High solubility in polar buffers
• Stability influenced by pH, ionic strength, and temperature

Ipamorelin:

• Selective GHSR‑1a agonist with low off‑target activity in vitro
• Predictable solubility and low nonspecific binding
• Stability improves in mildly acidic buffer systems

Combined Behaviour:

• Supports dual‑axis signalling analysis (cAMP, Ca²⁺, MAPK, CREB)
• Low aggregation risk when properly buffered
• Suitable for time‑course and receptor‑bias experiments

This dual-peptide formulation is commonly referenced in GHRH-R and GHSR-1a laboratory models, time-course assays, and receptor-bias experiments. It is a research convenience SKU, not a combined protocol for people.

• Store lyophilized material at −20 °C, protected from light and moisture
• Avoid repeated freeze–thaw cycles; aliquot according to your laboratory SOP

Batch Certificates of Analysis are listed in the certificates library when published. Match vial size and lot notes before assigning a lot to an assay.

Research use only. Not for human or veterinary use. No medical, cosmetic, or performance claims are made or implied.